EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Fibroblast growth factor 21 is a hepatokine involved in MASLD progression

Rocío Gallego-Durán iD, Javier Ampuero, Douglas Maya-Miles, Helena Pastor-Ramírez, Rocío Montero-Vallejo, Jesús Rivera-Esteban iD, Leticia Álvarez-Amor, María Jesús Pareja, María Carmen Rico, Raquel Millán, María José Robles-Frías, Rocío Aller und 17 weitere

United European Gastroenterology Journal · 2024-10 · 12 (8) · 1056-1068

DOI: 10.1002/ueg2.12534 ↗

Kurz gefasst

Fachartikel in der Zeitschrift United European Gastroenterology Journal, online erschienen am 18.06.2024. Verfasst von Rocío Gallego-Durán und 28 weiteren Autor:innen. Beteiligte Einrichtung: SeLiver Group, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Liver. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

We aimed to assess the role of FGF21 in metabolic dysfunction‐associated steatotic liver disease (MASLD) at a multi‐scale level.

Methods

We used human MASLD pathology samples for FGF21 gene expression analyses (qPCR and RNAseq), serum to measure circulating FGF21 levels and DNA for genotyping the FGF21 rs838133 variant in both estimation and validation cohorts. A hepatocyte‐derived cell line was exposed to free fatty acids at different timepoints. Finally, C57BL/6J mice were fed a high‐fat and choline‐deficient diet (CDA‐HFD) for 16 weeks to assess hepatic FGF21 protein expression and FGF21 levels by ELISA.

Results

A significant upregulation in FGF21 mRNA expression was observed in the liver analysed by both qPCR (fold change 5.32 ± 5.25 vs . 0.59 ± 0.66; p = 0.017) and RNA‐Seq (3.5 fold; FDR: 0.006; p < 0.0001) in MASLD patients vs . controls. Circulating levels of FGF21 were increased in patients with steatohepatitis vs . bland steatosis (386.6 ± 328.9 vs . 297.9 ± 231.5 pg/mL; p = 0.009). Besides, sex, age, A‐allele from FGF21, GG genotype from PNPLA3, ALT, type 2 diabetes mellitus and BMI were independently associated with MASH and significant fibrosis in both estimation and validation cohorts. In vitro exposure of Huh7.5 cells to high concentrations of free fatty acids (FFAs) resulted in overexpression of FGF21 ( p < 0.001). Finally, Circulating FGF21 levels and hepatic FGF21 expression were found to be significantly increased ( p < 0.001) in animals under CDA‐HFD.

Conclusions

Hepatic and circulating FGF21 expression was increased in MASH patients, in Huh7.5 cells under FFAs and in CDA‐HFD animals. The A‐allele from the rs838133 variant was also associated with an increased risk of steatohepatitis and significant and advanced fibrosis in MASLD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibroblast Growth FactorsLiverAdultAnimalsFemaleHumansMaleMiceMiddle AgedCell LineDiet, High-FatDisease ProgressionFatty Acids, NonesterifiedFatty LiverHepatocytesMice, Inbred C57BLNon-alcoholic Fatty Liver DiseasePolymorphism, Single NucleotideRNA, MessengerUp-Regulation

Stichwörter der Autor:innen

FGF21MASHMASLDNAFLDNASHfibroblast growth factor 21gene expressionhepatokinemetabolic syndromesteatohepatitis

Substanzen

Fatty Acids, NonesterifiedFGF21 protein, humanfibroblast growth factor 21Fibroblast Growth FactorsRNA, Messenger

Autor:innen und Institutionen

  • SeLiver Group, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
  • CIBEREHD, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.
  • Digestive Diseases Unit, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Liver Unit, Internal Medicine Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute for Research, Barcelona, Spain.
  • Andalusian Center of Molecular Biology and Regenerative Medicine-CABIMER- University Pablo Olavide-University of Seville-CSIC, Sevilla, Spain.
  • Biomedical Research Network on Diabetes and Related Metabolic Diseases-CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain.

ORCID-Profile: Rocío Gallego-Durán, Jesús Rivera-Esteban, José Luis Calleja

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Gallego-Durán, R., Ampuero, J., Maya-Miles, D., Pastor-Ramírez, H., Montero-Vallejo, R., Rivera-Esteban, J., Álvarez-Amor, L., Pareja, M. J., Rico, M. C., Millán, R., Robles-Frías, M. J., Aller, R., Rojas, Á., Muñoz-Hernández, R., Gil-Gómez, A., Gato, S., García-Lozano, M., Arias-Loste, M. T., Abad, J., …, & Romero-Gómez, M. (2024). Fibroblast growth factor 21 is a hepatokine involved in MASLD progression. United European Gastroenterology Journal, 12(8), 1056-1068. https://doi.org/10.1002/ueg2.12534

Vancouver

Gallego-Durán R, Ampuero J, Maya-Miles D, Pastor-Ramírez H, Montero-Vallejo R, Rivera-Esteban J, et al. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression. United European Gastroenterology Journal. 2024;12(8):1056-1068. doi:10.1002/ueg2.12534

BibTeX
@article{GallegoDurn2024,
  author = {Gallego-Durán, Rocío and Ampuero, Javier and Maya-Miles, Douglas and Pastor-Ramírez, Helena and Montero-Vallejo, Rocío and Rivera-Esteban, Jesús and Álvarez-Amor, Leticia and Pareja, María Jesús and Rico, María Carmen and Millán, Raquel and Robles-Frías, María José and Aller, Rocío and Rojas, Ángela and Muñoz-Hernández, Rocío and Gil-Gómez, Antonio and Gato, Sheila and García-Lozano, María and Arias-Loste, María Teresa and Abad, Javier and Calleja, José Luis and Andrade, Raúl J and Crespo, Javier and González-Rodríguez, Águeda and García-Monzón, Carmelo and Andreola, Fausto and Pericás, Juan Manuel and Jalan, Rajiv and Martín-Bermudo, Francisco and Romero-Gómez, Manuel},
  title = {Fibroblast growth factor 21 is a hepatokine involved in MASLD progression},
  journal = {United European Gastroenterology Journal},
  year = {2024},
  volume = {12},
  number = {8},
  pages = {1056--1068},
  doi = {10.1002/ueg2.12534}
}
Kostenlos starten →